IC-ONC Global (@IC_ONC) header
IC-ONC Global (@IC_ONC) profile picture

IC-ONC Global

@IC_ONC

Connect with a network of local and national thought leaders and clinicians responsible for treating patients with cancer. Likes/RT≠endorsement

IC-ONC.ORG
Joined February 2018
  • Tweets1.6K
  • Following3.1K
  • Followers535
331Media
Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)Photo by IC-ONC Global (@IC_ONC)
NEW CME ACTIVITY! 2 Multidisciplinary tumor boards discuss patient cases in melanoma/NSCLC & bladder/renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. bit.ly/4b47k5L
Image from IC-ONC Global (@IC_ONC)
69
IC-ONC Global retweeted
The ASCO Post (@ASCOPost) profile picture
The ASCO Post@ASCOPost11 Oct 2024
KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy ascopost.com/issues/october-… #gyncsm #cervicalcancer #immunotherapy #oncology
KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy

KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy

The phase III KEYNOTE-A18 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2024, found that treatment with the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with...

ascopost.com
6
11
1,856
Fusobacterium nucleatum (Fn) makes resistant microsatellite stable colorectal cancer respond better to anti-PD-1 therapy by boosting CD8+ T-cell function. High Fn levels could predict better outcomes with immunotherapy. #ColorectalCancer #Immunotherapy #Oncology @OncoAlert @Cancer_Cell DOI: 10.1016/j.ccell.2024.08.019
Image from Yüksel Ürün (@DrYukselUrun)
1
29
1
61
8,500
The hallmarks of cancer immune evasion: Cancer Cell cell.com/cancer-cell/fulltex…
The hallmarks of cancer immune evasion

The hallmarks of cancer immune evasion

Cancer cells often evade the host immune system, challenging the effectiveness of immunotherapy. In this comprehensive review, Galassi et al. summarize key mechanisms of immune evasion within the...

cell.com
29
NEW CME ACTIVITY! 2 Multidisciplinary tumor boards discuss patient cases in melanoma/NSCLC & bladder/renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. bit.ly/4b47k5L
Image from IC-ONC Global (@IC_ONC)
67
NEW CME ACTIVITY! 2 Multidisciplinary tumor boards discuss patient cases in melanoma/NSCLC & bladder/renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. bit.ly/4b47k5L
Image from IC-ONC Global (@IC_ONC)
1
129
Thanks @AACR for the profile. Hope all #immunotherapy & #immunology interested folks will join the Cancer Immunology Working Group (CIMM), particularly on LinkedIn for on-going discussions of the field!
Image from Jason Luke, MD, FACP, FASCO (@jasonlukemd)
11
43
3,224
IC-ONC Global retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJM19 Apr 2024
Adjuvant pembrolizumab was approved for patients with renal-cell carcinoma on the basis of improvements in disease-free survival observed in the KEYNOTE-564 trial. Data on overall survival are needed. Research findings are summarized in a Quick Take video: youtu.be/LM5rudCFfH8

Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM

Adjuvant pembrolizumab was approved for patients with renal-cell ca...

youtube.com
6
2
29
25,532
NEW CE ACTIVITY! bit.ly/4b47k5L 2 Multidisciplinary tumor boards in melanoma/NSCLC & bladder/renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. @ASCP_Chicago @UVaCME
Image from IC-ONC Global (@IC_ONC)
Image from IC-ONC Global (@IC_ONC)
34
NEW CME ACTIVITY! 2 Multidisciplinary tumor boards discuss patient cases in melanoma, NSCLC, bladder & renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. bit.ly/4b47k5L
Image from IC-ONC Global (@IC_ONC)
53
NEW CME ACTIVITY! 2 Multidisciplinary tumor boards discuss patient cases in melanoma, NSCLC, bladder & renal cell cancers. Strategies for ensuring patients receiving immunotherapy receive effective, timely, equitable biomarker testing, dx, tx & followup. bit.ly/4b47k5L
Image from IC-ONC Global (@IC_ONC)
42
IC-ONC Global retweeted
ASCP (@ASCP_Chicago) profile picture
ASCP
@ASCP_Chicago3 Jan 2024
Join us on January 18 for IC-ONC Annual Forum & participate in a case-based webinar designed to help cancer care teams stay up to date on advances in renal cell carcinoma & bladder cancer. Learn more & register now: bit.ly/47Km8W0 #SBP #SocietyOfBlackPathologists
Image from ASCP (@ASCP_Chicago)
1
3
589
The University of Virginia, @ASCP_Chicago & SBP are pleased to present the 2024 IC-ONC Annual Forum: A Series of Case Based Webinars January 18, Registration and more info: cmetracker.net/UVA/Publisher… Register soon to hold your spot!
Image from IC-ONC Global (@IC_ONC)
50
IC-ONC Global retweeted
IC-ONC Global (@IC_ONC) profile picture
IC-ONC Global@IC_ONC8 Dec 2023
🔥Todays the day @ noon eastern! 2024 IC-ONC Annual Forum: A Series of Case Based Webinars; Presented by The University of Virginia, @ASCP_Chicago & SBP See you then! 🎟️There is still time to register! December 8: cmetracker.net/UVA/Publisher… January 18: cmetracker.net/UVA/Publisher…
Image from IC-ONC Global (@IC_ONC)
1
92
🔥Todays the day @ noon eastern! 2024 IC-ONC Annual Forum: A Series of Case Based Webinars; Presented by The University of Virginia, @ASCP_Chicago & SBP See you then! 🎟️There is still time to register! December 8: cmetracker.net/UVA/Publisher… January 18: cmetracker.net/UVA/Publisher…
Image from IC-ONC Global (@IC_ONC)
1
92
The University of Virginia, @ASCP_Chicago & SBP are pleased to present the 2024 IC-ONC Annual Forum: A Series of Case Based Webinars Register soon to hold your spot! December 8 Register: cmetracker.net/UVA/Publisher… January 18 Register: cmetracker.net/UVA/Publisher… @UVaCME
Image from IC-ONC Global (@IC_ONC)
62
IC-ONC Global retweeted
IC-ONC Global (@IC_ONC) profile picture
IC-ONC Global@IC_ONC16 Nov 2023
The University of Virginia, @ASCP_Chicago & SBP are pleased to present the 2024 IC-ONC Annual Forum: A Series of Case Based Webinars Register soon to hold your spot! December 8 Register: cmetracker.net/UVA/Publisher… January 18 Register: cmetracker.net/UVA/Publisher… @UVaCME
Image from IC-ONC Global (@IC_ONC)
Image from IC-ONC Global (@IC_ONC)
1
150
IC-ONC Global retweeted
ASCP (@ASCP_Chicago) profile picture
ASCP
@ASCP_Chicago30 Nov 2023
Join us on December 8 for IC-ONC Annual Forum, where you will participate in a case-based webinar designed to help multidisciplinary cancer care teams stay updated on advances in melanoma & NSCLC. Learn more & register now: bit.ly/3GogcFO #SBP #SocietyOfBlackPathologists
Image from ASCP (@ASCP_Chicago)
6
7
996
The University of Virginia, @ASCP_Chicago & SBP are pleased to present the 2024 IC-ONC Annual Forum: A Series of Case Based Webinars Register soon to hold your spot! December 8 Register: cmetracker.net/UVA/Publisher… January 18 Register: cmetracker.net/UVA/Publisher… @UVaCME
Image from IC-ONC Global (@IC_ONC)
39
The University of Virginia, @ASCP_Chicago & SBP are pleased to present the 2024 IC-ONC Annual Forum: A Series of Case Based Webinars #Immunotherapy Register soon to hold your spot! 🎟️December 8 Register cmetracker.net/UVA/Publisher… 🎟️January 18 Register cmetracker.net/UVA/Publisher… @UVaCME
Image from IC-ONC Global (@IC_ONC)
1
94
Load more